Skip to main content

Table 1 Inclusion and exclusion criteria

From: Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients’ Experience on Rifaximin-α (PROSPER): an observational study among 550 patients

Inclusion criteria Exclusion criteria
• Diagnosis of cirrhosis • West Haven score of ≥2 at study entry
• Age ≥ 18 years • A mental health disorder that makes HE diagnosis questionable (e.g., dementia, psychosis)
• Enrolment within 12 weeks of resolution of an episode of overt HE associated with a hospital visit • Prior treatment with rifaximina within 12 months prior to the qualifying overt HE episode
• Ability to provide informed consent • Contraindications to the use of rifaximin-α 550 mg, as per the local Summary of Product Characteristics [16, 17]
• Clinical eligibility to receive rifaximin-α 550 mg, in the opinion of the participating physician, regardless of HE treatment actually received  
  1. HE hepatic encephalopathy
  2. aAll types and dose strengths of rifaximin